Last reviewed · How we verify
Combined Therapy SOF and DCV
This combination therapy uses sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir (an NS5A inhibitor) to block hepatitis C virus replication through dual inhibition of viral enzymes.
This combination therapy uses sofosbuvir (a nucleotide polymerase inhibitor) and daclatasvir (an NS5A inhibitor) to block hepatitis C virus replication through dual inhibition of viral enzymes. Used for Chronic hepatitis C virus infection (genotype-dependent).
At a glance
| Generic name | Combined Therapy SOF and DCV |
|---|---|
| Also known as | sofosbuvir, daclatasvir |
| Sponsor | Yassin Abdelghaffar Charity Center for Liver Disease and Research |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B polymerase and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Sofosbuvir inhibits the hepatitis C virus RNA-dependent RNA polymerase (NS5B), preventing viral RNA synthesis. Daclatasvir inhibits the NS5A protein, which is essential for viral replication and assembly. Together, these agents provide complementary antiviral activity with a high barrier to resistance development.
Approved indications
- Chronic hepatitis C virus infection (genotype-dependent)
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (PHASE4)
- Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus (PHASE2, PHASE3)
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- Re-treatment of HCV Following DAA Failure (NA)
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) (PHASE2, PHASE3)
- Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: